Evidence map›Paper›PMID 25115855›Full record

ArticlePloS one2014

Tetrandrine suppresses lipopolysaccharide-induced microglial activation by inhibiting NF-κB and ERK signaling pathways in BV2 cells.

Yalong Dang, Yongsheng Xu, Wentao Wu, Weiyi Li, Yanran Sun, Jing Yang, Yu Zhu, Chun Zhang

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 51 citations in OpenAlex.

  1. Polypeptides Isolated fromInternational journal of molecular sciences · 2022
    Article
  2. Medicinal Plants in the Treatment of Hypertension: A Review.Advanced pharmaceutical bulletin · 2021
    Review
  3. Article
  4. Role of glia in optic nerve.Progress in retinal and eye research · 2021
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yalong DangDepartment of Ophthalmology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, People's Republic of China; Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, People's Republic of China; Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.
Yongsheng XuClinical Stem Cell Research Center, Peking University Third Hospital, Beijing, People's Republic of China; Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.
Wentao WuClinical Stem Cell Research Center, Peking University Third Hospital, Beijing, People's Republic of China.
Weiyi LiClinical Stem Cell Research Center, Peking University Third Hospital, Beijing, People's Republic of China; Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.
Yanran SunDepartment of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.
Jing YangDepartment of Ophthalmology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, People's Republic of China.
Yu ZhuDepartment of Ophthalmology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, People's Republic of China.
Chun ZhangClinical Stem Cell Research Center, Peking University Third Hospital, Beijing, People's Republic of China; Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.
Peking University · CNFirst Affiliated Hospital of Zhengzhou University · CNPeking University Third Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveTetrandrine (TET) is a bisbenzylisoquinoline alkaloid extracted from Stephania tetrandra Moore. Recent studies have suggested that TET can reduce the inflammatory response in microglia, but the mechanisms remain unclear. The aim of this study is to investigate whether TET can inhibit lipopolysaccharide (LPS)-induced microglial activation and clarify its possible mechanisms. STUDY DESIGN/MATERIALS AND

methodsCell viability assays and cell apoptosis assays were used to determine the working concentrations of TET. Then, BV2 cells were seeded and pretreated with TET for 2 h. LPS was then added and incubated for an additional 24 hours. qRT-PCR and ELISA were used to measure the mRNA or protein levels of IL1β and TNFα. Western blotting was utilized to quantify the expression of CD11b and cell signaling proteins.

resultsTET at optimal concentrations (0.1 µM, 0.5 µM or 1 µM) did not affect the cell viability. After TET pretreatment, the levels of IL1β and TNFα (both in transcription and translation) were significantly inhibited in a dose-dependent manner. Further studies indicated that phospho-p65, phospho-IKK, and phospho-ERK 1/2 expression were also suppressed by TET.

conclusionsOur results indicate that TET can effectively suppress microglial activation and inhibit the production of IL1β and TNFα by regulating the NF-kB and ERK signaling pathways. Together with our previous studies, we suggest that TET would be a promising candidate to effectively suppress overactivated microglia and alleviate neurodegeneration in glaucoma.

Indexed as

AnimalsApoptosisBenzylisoquinolinesCD11b AntigenCell Line, TransformedCell SurvivalExtracellular Signal-Regulated MAP KinasesGene ExpressionInterleukin-1betaLipopolysaccharidesMiceMicrogliaNF-kappa BSignal TransductionTumor Necrosis Factor-alphaBenzylisoquinolinesCD11b AntigenExtracellular Signal-Regulated MAP KinasesInterleukin-1betaLipopolysaccharidesNF-kappa BtetrandrineTumor Necrosis Factor-alpha

Identifiers

PMID25115855
PMCPMC4130469
OpenAlexW1965242506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.